Abstract 97P
Background
EGFR inhibitors could increase MHC class-I presentation and sensitize tumor cells to CD8+ T cell–mediated killing, leading to a synergic efficacy in combination with PD-1 blockade. Afatinib also showed response as monotherapy in the treatment of refractory esophageal squamous cell carcinoma (ESCC). Herein, we report preliminary results of a phase II study of BI-754091 and afatinib in refractory ESCC patients.
Methods
Patients with refractory ESCC were eligible to receive afatinib 30 mg once daily and BI-754901 240 mg on day 1, in a 3-week cycle. With Optimal Simon’s two-stage design and (p0=0.17, p1=0.35) for objective response rate (ORR, proportion of patients with complete or partial response [CR/PR]) and given error probabilities (one-sided alpha=0.05; beta=0.2), 16 evaluable patients were needed in the first stage. If 4 or more patients with objective response, the study would be extended to the second stage. Tumor response was assessed by CT/MRI every 6 weeks according to RECIST v1.1. The PR should be confirmed by two consecutive image examinations.
Results
Between August 2021 and February 2022, a total of 19 patients were enrolled as the intention-to-treat (ITT) population. Three patients withdrew early after the first cycle of treatment. With a median follow-up of 7.4 months (95% confidence interval [CI], 5.2-7.9), 7 patients achieved confirmed PR and 7 patients (36.8%) got stable disease, with the ORR of 36.8% (95% CI, 16-62%) in ITT population. The median progression-free survival was 5.3 months (95% CI, 3.8-6.1) in 16 evaluable cases. The common all grades of adverse events were afatinib-related diarrhea (47.5%), mucositis (36.9%), acneiform rash (31.6%). One patient suffered from grade 2 pneumonitis. No treatment-related death was reported.
Conclusions
By the observation of 7 patients with confirmed PR in the first stage, the second stage would be started for final enrollment to 44 evaluable cases.
Clinical trial identification
NCT04839471.
Editorial acknowledgement
Legal entity responsible for the study
The authors without further recourse to the authors.
Funding
Boehringer Ingelheim.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
79P - Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase III HIMALAYA study
Presenter: Arndt Vogel
Session: Poster viewing 02
82P - A randomized controlled, open-label, adaptive phase III clinical trial to evaluate safety and efficacy of EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas after FOLFIRINOX
Presenter: Muh-Hwan Su
Session: Poster viewing 02
83P - Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster viewing 02
84P - Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large real life worldwide population
Presenter: Margherita Rimini
Session: Poster viewing 02
86P - Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study
Presenter: Aiwu Ruth He
Session: Poster viewing 02
87P - Socio-demographic disparities in esophageal cancer: A SEER analysis
Presenter: Beas Siromoni
Session: Poster viewing 02